Brief: Sequana Medical: Positive Interim Data From North American Pivotal POSEIDON Study of Alfapump

Sequana Medical NV

19/11/2020 06:20

Nov 19 (Reuters) - Sequana Medical NV  SEQUA.BR :
    * SEQUANA MEDICAL ANNOUNCES POSITIVE INTERIM DATA FROM NORTH
AMERICAN PIVOTAL ALFAPUMP® STUDY (POSEIDON)
    * RESULTS FROM FIRST 13 PATIENTS IN ROLL-IN COHORT SHOWED
OVER 90%
REDUCTION IN MEAN FREQUENCY OF THERAPEUTIC PARACENTESIS VERSUS
BASELINE
    * INTERIM DATA OF FULL ROLL-IN COHORT EXPECTED IN H1 2021
    * SAFETY PROFILE IN LINE WITH EXPECTATIONS

Source text for Eikon:  ID:nNDL7rT8vl 
Further company coverage:  SEQUA.BR 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))